Endogena Therapeutics Program
Retinitis Pigmentosa
Key Facts
About Centenara Labs
Centenara Labs is a pioneering longevity-focused biotech that builds and invests in a diversified portfolio of companies targeting geriatric diseases through the lens of aging biology. Its strategy involves de-risking early scientific discoveries by providing a platform of experienced drug developers, business leaders, and capital. With a pipeline built around the hallmarks of aging, the company has progressed two ophthalmology programs into the clinic and is advancing several pre-clinical assets in fibrosis, cancer, and sarcopenia, aiming to create optimal exit scenarios to fund new ventures.
View full company profileAbout Centenara Labs
Centenara Labs is a pioneering longevity-focused biotech that builds and invests in a diversified portfolio of companies targeting geriatric diseases through the lens of aging biology. Its strategy involves de-risking early scientific discoveries by providing a platform of experienced drug developers, business leaders, and capital. With a pipeline built around the hallmarks of aging, the company has progressed two ophthalmology programs into the clinic and is advancing several pre-clinical assets in fibrosis, cancer, and sarcopenia, aiming to create optimal exit scenarios to fund new ventures.
View full company profileTherapeutic Areas
Other Retinitis Pigmentosa Drugs
| Drug | Company | Phase |
|---|---|---|
| BS01 | Bionic Sight | Phase 1/2 |
| jCell | jCyte | Phase 3 |
| EA-2353 | Endogena Therapeutics | Phase I/IIa |
| NPI-001 | Nacuity Pharmaceuticals | Phase 2/3 |
| MCO-010 | Nanoscope Therapeutics | Phase 2/3 |
| RTx-015 | Ray Therapeutics | Phase 1 |
| OCU400 | Ocugen | Phase 3 |
| ADX-2191 | Aldeyra Therapeutics | Phase 2 |